이 페이지의 번역은 실험적이며 개발 중입니다. 여러분의 환영합니다!

Bavarian Nordic 관리

관리 기준 확인 3/4

현재 CEO에 대한 정보가 충분하지 않습니다.

주요 정보

Paul Chaplin

최고 경영자

DKK 23.4m

총 보상

CEO 급여 비율	30.7%
CEO 임기	10yrs
CEO 소유권	0.1%
경영진 평균 재임 기간	4.4yrs
이사회 평균 재임 기간	3.4yrs

최근 관리 업데이트

Recent updates

CEO 보상 분석

Paul Chaplin 의 보수는 Bavarian Nordic 의 수익과 비교하여 어떻게 변경되었나요?
날짜	총 보상	급여	회사 수익
Mar 31 2024	n/a	n/a	DKK 984m
Dec 31 2023	DKK 23m	DKK 7m	DKK 1b
Sep 30 2023	n/a	n/a	DKK 723m
Jun 30 2023	n/a	n/a	DKK 1b
Mar 31 2023	n/a	n/a	DKK 301m
Dec 31 2022	DKK 22m	DKK 6m	-DKK 347m
Sep 30 2022	n/a	n/a	-DKK 599m
Jun 30 2022	n/a	n/a	-DKK 693m
Mar 31 2022	n/a	n/a	-DKK 606m
Dec 31 2021	DKK 18m	DKK 6m	-DKK 465m
Sep 30 2021	n/a	n/a	-DKK 737m
Jun 30 2021	n/a	n/a	-DKK 629m
Mar 31 2021	n/a	n/a	-DKK 368m
Dec 31 2020	DKK 14m	DKK 5m	DKK 278m
Sep 30 2020	n/a	n/a	DKK 606m
Jun 30 2020	n/a	n/a	DKK 481m
Mar 31 2020	n/a	n/a	DKK 267m
Dec 31 2019	DKK 12m	DKK 5m	-DKK 347m
Sep 30 2019	n/a	n/a	-DKK 402m
Jun 30 2019	n/a	n/a	-DKK 271m
Mar 31 2019	n/a	n/a	-DKK 279m
Dec 31 2018	DKK 12m	DKK 6m	-DKK 362m
Sep 30 2018	n/a	n/a	-DKK 445m
Jun 30 2018	n/a	n/a	-DKK 151m
Mar 31 2018	n/a	n/a	DKK 5m
Dec 31 2017	DKK 13m	DKK 5m	DKK 181m

보상 대 시장: Paul 의 총 보상 ($USD 3.38M )은 UK 시장( $USD 2.38M ).

보상과 수익: Paul 의 보상은 지난 한 해 동안 회사 성과와 일치했습니다.

CEO

Paul Chaplin (57 yo)

10yrs

테뉴어

DKK 23,428,000

보상

Dr. Paul John Chaplin, M.Sc., Ph D., has been the Chief Executive Officer and President at Bavarian Nordic A/S since May 28, 2014. Dr. Chaplin served as an Executive Vice President of Bavarian Nordic A/S f...

리더십 팀

이름	위치	테뉴어	보상	소유권
Paul Chaplin	CEO & President	10yrs	DKK 23.43m	0.11% DKK 15.8m
Henrik Juuel	CFO & Executive VP	5.6yrs	DKK 12.23m	데이터 없음
Russell Thirsk	Executive VP & COO	2.2yrs	데이터 없음	데이터 없음
Rolf Sørensen	Vice President of Investor Relations & Communications	no data	데이터 없음	데이터 없음
Anu Kerns	Executive VP and Chief People & Sustainability Officer	3.6yrs	데이터 없음	데이터 없음
Jean-Christophe May	Executive VP & Chief Commercial Officer	4.4yrs	데이터 없음	데이터 없음

4.4yrs

평균 재임 기간

57yo

평균 연령

경험이 풍부한 관리: BAVAC 의 관리팀은 경험 ( 4.4 년 평균 재직 기간)으로 간주됩니다.

이사회 구성원

이름	위치	테뉴어	보상	소유권
Peter Kürstein-Jensen	Independent Director	12.2yrs	DKK 740.00k	0.026% DKK 3.8m
Anders Pedersen	Deputy Chairman	14.2yrs	DKK 1.13m	0.024% DKK 3.5m
Franciscus A. G. Verwiel	Independent Director	8.2yrs	DKK 830.00k	0.0055% DKK 806.9k
Anne Eberhard	Independent Director	5.2yrs	DKK 860.00k	0.0035% DKK 506.9k
Luc Debruyne	Independent Chairman	1.3yrs	DKK 1.43m	데이터 없음
Heidi Hunter	Independent Director	1.4yrs	DKK 635.00k	데이터 없음
Linette Munksgaard Andersen	Employee-Elected Member of the Board	3.4yrs	DKK 475.00k	0.00070% DKK 102.0k
Thomas Alex Bennekov	Employee-Elected Member of the Board	3.4yrs	DKK 475.00k	0.0024% DKK 348.1k
Anja Gjol	Employee-Elected Member of the Board	3.4yrs	DKK 475.00k	0.00070% DKK 102.0k
Karen Merete Jensen	Employee-Elected Member of the Board	3.4yrs	DKK 475.00k	0.00088% DKK 128.2k
Johan Hoof	Independent Director	1.4yrs	DKK 575.00k	데이터 없음
Montse Picart	Independent Director	less than a year	데이터 없음	데이터 없음

3.4yrs

평균 재임 기간

62yo

평균 연령

경험이 풍부한 이사회: BAVAC 의 이사회는 경험(평균 재직 기간 3.4 년)으로 간주됩니다.

Bavarian Nordic 관리

관리 기준 확인 3/4

주요 정보

최근 관리 업데이트

Laurence De Moerlooze to Leave Bavarian Nordic A/S as Executive Vice President and Chief Medical Officer

Less than half of directors are independent

Less than half of directors are independent

Less than half of directors are independent

Less than half of directors are independent

Bavarian Nordic A/S, Annual General Meeting, Apr 16, 2024

Recent updates

Bavarian Nordic A/S Submits Marketing Authorization Application for Its Chikungunya Vaccine Candidate to Ema

Laurence De Moerlooze to Leave Bavarian Nordic A/S as Executive Vice President and Chief Medical Officer

Bavarian Nordic A/S Provides Earnings Guidance for the Year 2024

Bavarian Nordic A/S Initiates Rolling Submission of Biologics License Application with FDA for Chikungunya Vaccine Candidate

Bavarian Nordic A/S Receives Approval of Smallpox and Mpox Vaccine in Switzerland

Less than half of directors are independent

Less than half of directors are independent

Bavarian Nordic A/S Provides Revenue Guidance for the Year 2024

Less than half of directors are independent

Less than half of directors are independent

Bavarian Nordic A/S Provides Earnings Guidance for the Year 2023

Bavarian Nordic A/S's Mpox Vaccine Receives Recommendation from U.S. CDC Advisory Committee for Routine Use in Adults at Risk

Bavarian Nordic A/S Reports Additional Phase 3 Results and Provides Update on Development Program for its cVLP-Based COVID-19 Booster Vaccine Candidate, ABNCoV2

Bavarian Nordic A/S, Annual General Meeting, Apr 16, 2024

Less than half of directors are independent

Bavarian Nordic A/S Provides Update on RSV Vaccine Program

Bavarian Nordic A/S Reports Data from A Phase 3 Clinical Trial of Its Vlp-Based Chikungunya Virus Vaccine in Adults >=65 Years of Age Study Successfully Met Its Primary Endpoints

Bavarian Nordic A/S Reports 12-Month Durability Data from Phase 2 Clinical Trial of Covid-19 Vaccine Candidate

Bavarian Nordic A/S acquired Travel health business of Emergent International Inc. and Emergent Travel Health Inc. for $384 million.

Bavarian Nordic A/S Provides Earnings Guidance for the Year 2023

Less than half of directors are independent

Less than half of directors are independent

Less than half of directors are independent

Less than half of directors are independent

Full year 2022 earnings released: kr.4.90 loss per share (vs kr.7.37 loss in FY 2021)

Bavarian Nordic A/S entered into an agreement to acquire Travel health business of Emergent International Inc. and Emergent Travel Health Inc. for $380 million.

Bavarian Nordic A/S entered into an agreement to acquire Travel health business of Emergent International Inc. and Emergent Travel Health Inc. for $380 million.

Bavarian Nordic A/S Provides Earnings Guidance for Fiscal Year 2023

Less than half of directors are independent

Bavarian Nordic A/S Provides Revenue Guidance for Fiscal Year 2022

Bavarian Nordic Completes Enrollment in Global Phase 3 Trial of RSV Vaccine Candidate for Older Adults

Chairman recently sold kr.508k worth of stock

Less than half of directors are independent

Bavarian Nordic A/S Maintains Earnings Guidance for the Year 2022

Bavarian Nordic A/S Announces Covid-19 Booster Vaccine Candidate Demonstrates Durable Antibody Response Six Months After Vaccination in Phase 2 Clinical Trial

Bavarian Nordic A/S Appoints Luc Debruyne as Board of Directors

Less than half of directors are independent

Bavarian Nordic A/S Revises Earnings Guidance for the Full Year 2022

Bavarian Nordic Announces Initiation of a Global Phase 3 Clinical Trial of its COVID-19 Booster Vaccine Candidate

Less than half of directors are independent

Bavarian Nordic A/S, Annual General Meeting, Mar 30, 2023

Bavarian Nordic A/S to Report Fiscal Year 2022 Final Results on Mar 02, 2023

Bavarian Nordic A/S Provides Revenue Guidance for the Year 2022

Less than half of directors are independent

Bavarian Nordic A/S Receives U.S. and Eu Approvals of Its Fill and Finish Vaccine Manufacturing Facility

Bavarian Nordic A/S Receives Positive CHMP Opinion on the Extension of Vaccine Label to Include Monkeypox

Bavarian Nordic A/S Raises Earnings Guidance for the Financial Guidance for 2022

Less than half of directors are independent

Bavarian Nordic A/S Provides an Update on the Phase 3 Development of ABNCoV2, A VLP-Based, Non-Adjuvanted Covid-19 Booster Vaccine Candidate

Bavarian Nordic A/S Revises Revenue Guidance for the Year 2022

Bavarian Nordic A/S Raises Financial Guidance for the Year 2022

Bavarian Nordic A/S Maintains Earnings Guidance for the Year 2022

Bavarian Nordic Reports Omicron Data from Phase 2 Trial of Its Covid-19 Booster Vaccine Candidate

Bavarian Nordic Announces Initiation of A Global Phase 3 Clinical Trial of Its RSV Vaccine Candidate in Older Adults

High number of new directors

Bavarian Nordic A/S Provides Revenue Guidance for the Full Year of 2022

Bavarian Nordic A/S Reports Additional Positive Phase 2 Results for Its Covid-19 Vaccine Candidate Ahead of Phase 3 Trial

Bavarian Nordic Announces Breakthrough Therapy Designation for Its RSV Vaccine Candidate for the Prevention of Respiratory Syncytial Virus in Older Adults

High number of new directors

Bavarian Nordic Commits to Initiating Phase 3 Trial of RSV Vaccine Candidate and to Strengthening its Capital Base

High number of new directors

Bavarian Nordic A/S announced a financing transaction

Third quarter 2021 earnings released: kr.1.30 loss per share (vs kr.0.50 profit in 3Q 2020)

High number of new directors

Bavarian Nordic A/S Provides Revenue Guidance for the Year 2021

Bavarian Nordic Initiates Phase 2 Clinical Trial of COVID-19 Booster Vaccine

Bavarian Nordic A/S Reports Initial Results from First-in-Human Trial of COVID-19 Vaccine

First quarter 2021 earnings released

Bavarian Nordic A/S Maintains Earnings Guidance for the Full Year 2021